Nasdaq:US$13.90 (+1.50) | HKEX:HK$21.60 (+1.00) | AIM:£2.36 (+0.25)
Announcements
1
2345678910111213
found Documents: 650
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets   Hong Kong, Shanghai & Florham Park, NJ — Tuesday, November 15, 2022: HUTCHMED (China) Limited (“HUTCHMED”)
Read More
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant
Read More
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab a
Read More
Hong Kong, Shanghai & Florham Park, NJ — Friday, October 21, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on O
Read More
Hong Kong, Shanghai & Florham Park, NJ –– Monday, October 10, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm anti
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, September 14, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on September 13, 2022, it granted share options under the Share Option Scheme adopted by
Read More
— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-b
Read More
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation a
Read More
San Diego, Shanghai and Hong Kong — Tuesday, August 9, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in the United State
Read More
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to
Read More
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway —   Hong Kong, Shanghai & Florh
Read More
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with hig
Read More
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient receiv
Read More
— HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies — Hong Kong, Shanghai & Florham Park, NJ — Friday, July 15, 2022: HUTCH
Read More
— 49% ORR amongst SAVANNAH patients with higher MET levels — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 13, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of
Read More
San Diego, Shanghai, Hong Kong and Sydney — Wednesday, July 6, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australi
Read More
Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 29, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:   1. Name of
Read More
Hong Kong, Shanghai & Florham Park, NJ — Monday, June 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Pr
Read More
The English and Chinese versions of the 2021 Sustainability Report (the “Sustainability Report”) are available on the website of the Company at www.hutch-med.com and that of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 24, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on May 23, 2022, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive
Read More
Hong Kong, Shanghai & Florham Park, NJ — Monday, May 16, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 an
Read More
HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 2, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) anno
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 27, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual G
Read More
Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 21, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on A
Read More
Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 31, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status under the Holding Foreign Companies Accountable Act (th
Read More
Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, March 23, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report together with the Notice of Annual General Meeting and the For
Read More
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 11, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an update on its status under the Holding Foreign Companies Account
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 9, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2021 annual results of HUTCHMED on March 3, 2022, the follo
Read More
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 7, 2022: (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:​
Read More
Hong Kong, Shanghai & Florham Park, NJ – Thursday, March 3, 2022: (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces: the retirement of Mr. Christian Hogg after almost 22 years with the Company, including
Read More
Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches of SULANDA® and ORPATHYS®; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS® in lung cancer, kidne
Read More
— First homegrown innovative medicine approved in Macau based on China clinical data — Hong Kong, Shanghai & Florham Park, NJ –– Tuesday, March 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today an
Read More